Replies to post #242833 on Avid Bioservices Inc (CDMO)

[biopharm]

Could have the late Dr. Andrew Parsa also been on the fast track to quickly learning re: PS Targeting ?

This becomes a little shocking. Now, Dr. Wolchok has been working with platforms from the late (both young..) Dr. Philip Thorpe / Dr. Andrew Parsa.

Now we have a few immunotherapy researchers where many years were taken and cut short, en route to some historic paradigm shifts in medical treatment they would be part of changing Big Pharma legacy ways. Along with the late Dr. Phil Thorpe and Dr. Andrew Parsa... we can include Dr. Alan Escher:

Alan P. Escher, Ph.D.

Dr. Alan Escher received his BSc magna cum laude from the University of Connecticut and PhD from Cornell University. Dr. Escher was previously Associate Professor and Associate Director of the Center for Transplant Immunology Research at the Loma Linda University School of Medicine, where he and his colleagues started to develop pro-apoptotic DNA vaccination for the treatment of type 1 diabetes. His laboratory was among the first to report the beneficial effects of DNA vaccination for type 1 diabetes in 1999. Later, his team successfully translated the technology to prevention of skin allograft rejection as proof-of-concept for application to organ transplantation. In 2009, he began his transition from the academic setting. He co-founded SEKRIS Biomedical to translate apoptotic DNA immunotherapy for treatment of inflammatory disorders. As Executive Vice President of Technology Development, he continued to strengthen the patent portfolio. While his presence will be sorely missed, Dr. Escher’s legacy will continue through continued development of his work and realization of his vision to control unwanted inflammation with the ADI technology.

http://sekrisbiomedical.com/alan-escher/

Alice Li / Alan Escher ...

Publications

Alice Li and Alan Escher (2013). DNA Immunotherapies for Type 1 Diabetes – Type 1 Diabetes, Alan P. Escher and Alice Li (Eds.), ISBN: 978-953-51-1017-0, InTech. Chapter

Alice Li and Alan Escher (2011). Immunotherapy for Type 1 Diabetes – Preclinical and Clinical Trials, Type 1 Diabetes – Pathogenesis, Genetics and Immunotherapy, David Wagner (Ed.), ISBN: 978-953-307-362-0, InTech. Chapter

...
...
http://sekrisbiomedical.com/publications/

http://www.ctl.cornell.edu/about/staff/staff-members.php?sid=6

...
...The long-term goal is to ameliorate other inflammatory disorders including organ rejection. (I am 100% positive that PS Targeting would assist organ transplants)

sekrisbiomedical.com/company/

-------------------------------------

Shahrokh Shabahang

President at SEKRIS Biomedical, Inc.
Redlands, California
Biotechnology

Current
SEKRIS Biomedical, Inc., Loma Linda University

Previous
Victor Valley Endodontics, Genelux Corporation, University of the Pacific

Education
Loma Linda University

Experience
Co-founder and President/CEO
SEKRIS Biomedical, Inc.
July 2009 – Present (6 years 6 months)

Associate Professor
Loma Linda University
July 1997 – Present (18 years 6 months)

Endodontist/Partner
Victor Valley Endodontics
September 2005 – May 2010 (4 years 9 months)Victorville, CA

Private practice in endodontics
Director of Clinical Operations and Board Secretary
Genelux Corporation
August 2004 – November 2007 (3 years 4 months)Redlands, California

Assistant Professor
University of the Pacific
April 1992 – June 1995 (3 years 3 months)San Francisco, CA

Dentist/Partner
Sunnyvale Dental Care, Inc.
October 1987 – May 1995 (7 years 8 months)Sunnyvale, CA

Private practice in dentistry

Companies

Loma Linda University

Novo Nordisk

Sanford Health

Dakota Venture Group
Venture Capital & Private Equity

New Enterprise Associates (NEA)
Venture Capital & Private Equity

..
..
https://www.linkedin.com/in/shahrokh-shabahang-b02b4451

How may it fit in with Peregrine? well I've posted about many of the above, separate items... but James Carlson has ties to Sekris and Dakota Venture Group ties to NDSU and New Enterprise Associates ties to BMS...... of course we had the CSM ties to NDSU..etc..etc. More to come... but I am 100% that some know exactly how far some had gone to target Peregrine Pharmaceuticals.

James D. Carlson -68

Fargo, ND
West Fargo, ND
Stanley, ND
Redlands, CA
Charleston, SC

Pracs Institute , Ltd.
James Doran Company
Dakota REIT Management LLC
Cetero Research Company
Sekris Biomedical Inc
Research Corridor

Studied at:
University of Iowa

Relatives:
Sara Carlson
Chad Carlson
Christopher Carlson
Kathy Carlson
Joshua Carlson
Sonya Carlson

http://www.intelius.com/Find-Phone-Address/Fargo-ND/James-Carlson.html

[biopharm]

..and remember, Agenus does have "unclassified.." work in their pipeline so they just may be another Peregrine collaborator, "ESPECIALLY" since we know see the facts that Dr. Jedd Wolchok was already working with Dr. Andrew Parsa... just as he is now working with Peregrine and the paradigm shifting technology of PS Targeting founded, discovered and advanced by the late Dr. Philip Thorpe

The new BODs should have a mission right now and that is to disclose all undisclosed program partners, all undisclosed targets that were being worked on and it would also seal the deal once all transcripts / depositions / court records unsealed, because was Peregrine IP of PS Targeting being used by Agenus? Very possibly yes

I say all should demand all records before any deal takes place because many shareholders will likely be shocked in the future ....to find out about certain collaborators and PS Targeting values as it is Right Now trying to be breadcrumbed out of our hands.

CHECKPOINT DEVELOPMENT PROGRAMS
Agenus has a portfolio of more than 10 antibodies that target both foundational inhibitory checkpoints, such as CTLA-4 and PD-1, as well as novel, cutting-edge targets that we feel could provide exciting opportunities as research continues to emerge on their potential. In addition to CTLA-4 and PD-1 our initial disclosed targets include GITR, OX40, TIM-3 and LAG-3. We also have many undisclosed checkpoint targets. Lead candidates for our CTLA-4, GITR, OX40 and PD-1 programs were discovered during an earlier collaboration with Ludwig Cancer Research.

http://agenusbio.com/pipeline/checkpoint-program/

It becomes more clouded now, WHY the new BODs are aligning up to block these requests and records....just ask why???

Read and listen to the video, all this was in perfect timeline of Peregrine past CEO Steve King disclosing dozens of "undisclosed Collaborations" and Agenus some as well...

Dr. Andrew Parsa, neurosurgeon at Northwestern Memorial Hospital, is creating a vaccine from the tumor itself to help the immune system target and suppress the cancer.
http://abc7chicago.com/archive/9546480/

CONTACT US
keyboard_arrow_left Back to Press Releases
NM News Blog
Press Releases
NM In The News
Media Relations
Northwestern Medicine Northwestern Medicine Logo Northwestern Medicine Logo
Northwestern Medicine Enrolls First Participant in Midwest for Research Study of Personalized Vaccine for Aggressive Brain Tumors
NORTHWESTERN MEMORIAL HOSPITAL
AUGUST 13, 2013
Randomized phase II trial will investigate vaccine therapy combined with Avastin for patients with recurrent glioblastoma multiforme

CHICAGO, IL – Northwestern Medicine® recently joined a landmark clinical trial to investigate if a vaccine made from a patient’s own brain tumor is effective in slowing tumor progression and extending survival. The randomized phase II trial will study how well giving the study vaccine with or without Avastin (bevacizumab) works in treating patients with recurrent glioblastoma multiforme (GBM). The study is the largest randomized brain tumor vaccine trial ever funded by the National Cancer Institute (NCI) and is chaired by Andrew T. Parsa, MD, PhD, who joined Northwestern Memorial Hospital in July as the new chair of neurological surgery. The first participant in the Midwest, and only third in the country, was enrolled in the trial last week at Northwestern Memorial.

The trial will enroll more than 200 participants with recurrent glioblastoma that can be surgically removed. Following the participant’s surgery, the tumor is sent to an industry collaborator Agenus Inc., where the participant’s specific personalized vaccine, designated as HSPPC-96, is created. The vaccine is unique to the individual participant and is engineered to trigger an immune system response to kill tumor cells that may remain following surgery.

“This is truly personalized medicine where the patient’s own tumor is being used to help fight their cancer,” said Parsa, who is also the Michael J. Marchese Professor and chair of the department of neurological surgery at Northwestern University Feinberg School of Medicine and a member of the of Robert H. Lurie Comprehensive Cancer Center of Northwestern University and part of the Northwestern Brain Tumor Institute. “The vaccine provokes a tumor-specific immune response that is specific to that patient. The T cells, which are the part of the immune system that fights disease, tracks down the cancer cells and kills them.”

Parsa launched this area of research in 2006 at the University of California, San Francisco (UCSF). Previous phases of this research have returned promising results finding that the vaccine extended survival for participants with glioblastoma when compared to standard therapies. In this next phase, researchers are seeking to understand if the vaccine is safe and more effective when given with Avastin, a drug that is known to shrink brain tumors and is a standard therapy for recurrent glioblastoma. Trial participants will be randomized to either receive the vaccine alone, concurrently with Avastin or Avastin only. Jeffrey Raizer, MD, co-director of the Northwestern Brain Tumor Institute (NBTI), is the principal investigator for the trial at Northwestern.

“This vaccine therapy has the potential to extend the lives of patients who often have limited options when their tumor returns,” said Raizer, medical director of neuro-oncology at Northwestern Memorial, associate professor of neurology at the Feinberg School and a member of the Lurie Cancer Center. “Previous results indicate that we may be able to extend survival longer by combining the therapy with other drugs, such as Avastin, that may boost the immune response of the vaccine.”

https://www.nm.org/about-us/northwestern-medicine-newsroom/press-releases/2013/northwestern-medicine-enrolls-first-participant#.U7F0u5RdU3c

There are many relevant posts this is connected to which gives high probability that Peregrines IP of PS Targeting was under collaborations with Dr Andrew Parsa and the question remains, WHY are records being hidden and remain closed....I mean since Renegade Roger Lias says the PS Targeting pipeline has only residual value ....

Then WHY are they hiding the residual research records of all collaborators? Why?